Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AEV 5000

Next Previous
Drug Profile

AEV 5000

Alternative Names: AEV-5000

Latest Information Update: 16 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AevisBio
  • Developer AevisBio; Korea Research Institute of Chemical Technology
  • Class Antineoplastics
  • Mechanism of Action Proteolysis
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 09 Mar 2022 AevisBio and Korea Research Institute of Chemical Technology enters a R&D agreement to develop anti-cancer therapies (AevisBio pipeline, March 2022)
  • 09 Mar 2022 Early research in Solid tumours in South Korea (unspecified route) (AevisBio pipeline, March 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top